# Recursion (RXRX) — Earnings

RXRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rxrx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.25 |
| EPS estimate | −$0.24 |
| EPS surprise | −4.17% |
| Revenue surprise | −33.42% |
| Revenue | $7.3M |
| Revenue estimate | $11.0M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1601830/000160183026000098/rxrx-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/a7564764-6661-8bdf-1e4f-7d6d59206fe9.html) |

Recursion reported Q2 2026 results on August 5, 2026, with a loss of $0.25 per share. That was 4.17% wider than the estimated $0.24 loss. Revenue of $7.3 million fell short of the $11.0 million consensus. Compared with Q2 2025, the loss narrowed from $0.41 per share, but revenue was about 62% lower than the $19.1 million of a year earlier.

Recursion lost money in all 20 quarters in the table. Annual losses were $1.37 per share in 2022, $1.57 in 2023, $1.66 in 2024 and $1.48 in 2025. Revenue is small and uneven from quarter to quarter. It rose to $74.3 million in 2025, about 27% more than in 2024, with Q4 2025 alone contributing $35.4 million, the quarterly high in the table. The last three quarterly losses, between $0.21 and $0.25 per share, are the narrowest in the table. Against EPS estimates the record is mixed, with 8 beats, 11 misses and one match.

Recursion reported third-quarter results between November 5 and November 10 in each of the past five years, pointing to early November 2026 for the next report. It will show whether the narrower losses of recent quarters hold.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | −$0.24 | −$0.25 | -4.17% | $11.0M | $7.3M |
| Q1 2026 | May 6, 2026 | −$0.27 | −$0.22 | 16.98% | $15.8M | $6.3M |
| Q4 2025 | Feb 25, 2026 | −$0.29 | −$0.21 | 27.59% | $21.1M | $35.4M |
| Q3 2025 | Nov 5, 2025 | −$0.38 | −$0.36 | 4.53% | $16.9M | $5.0M |
| Q2 2025 | Aug 5, 2025 | −$0.35 | −$0.41 | -16.05% | $15.4M | $19.1M |
| Q1 2025 | May 5, 2025 | −$0.52 | −$0.50 | 3.10% | $15.0M | $14.8M |
| Q4 2024 | Feb 28, 2025 | −$0.41 | −$0.53 | -28.83% | $15.3M | $4.5M |
| Q3 2024 | Nov 6, 2024 | −$0.33 | −$0.34 | -2.16% | $18.7M | $26.1M |
| Q2 2024 | Aug 8, 2024 | −$0.38 | −$0.40 | -4.09% | $12.0M | $14.4M |
| Q1 2024 | May 9, 2024 | −$0.42 | −$0.39 | 7.87% | $11.1M | $13.5M |
| Q4 2023 | Feb 27, 2024 | −$0.45 | −$0.42 | 6.42% | $19.9M | $10.6M |
| Q3 2023 | Nov 9, 2023 | −$0.39 | −$0.43 | -11.57% | $11.2M | $10.1M |
| Q2 2023 | Aug 8, 2023 | −$0.38 | −$0.38 | -1.33% | $11.9M | $11.0M |
| Q1 2023 | May 8, 2023 | −$0.35 | −$0.34 | 2.47% | $12.8M | $12.1M |
| Q4 2022 | Feb 27, 2023 | −$0.29 | −$0.31 | -6.90% | $23.8M | $13.7M |
| Q3 2022 | Nov 8, 2022 | −$0.38 | −$0.35 | 7.58% | $6.8M | $13.1M |
| Q2 2022 | Aug 9, 2022 | −$0.37 | −$0.38 | -1.79% | $5.3M | $7.7M |
| Q1 2022 | May 10, 2022 | $0.10 | −$0.33 | -430.00% | $84.0M | $5.3M |
| Q4 2021 | Mar 23, 2022 | −$0.31 | −$0.38 | -23.90% | $6.0M | $2.5M |
| Q3 2021 | Nov 10, 2021 | −$0.28 | −$0.28 | 0.00% | $2.7M | $2.5M |

## Frequently Asked Questions

### When did Recursion (RXRX) last report earnings?

Recursion last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did RXRX beat earnings estimates?

No. Recursion reported EPS of −$0.25 for Q2 2026 against a −$0.24 estimate — a 4.17% miss.

### How much revenue did RXRX report last quarter?

Recursion reported $7.3M in revenue for Q2 2026, against a consensus estimate of $11.0M.

## Similar Stocks

- [CRSP](https://www.lighthorse.io/tickers/crsp) — CRISPR Therapeutics AG - Common Shares

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).